The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Tzifi, Flora ^a,b   Economopoulou, Christina ^a   Gourgiotis, Dimitrios ^a   Ardavanis, Alexandros ^c   Papageorgiou, Sotirios ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ASPARAGINASE; BH3 PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; NAVITOCLAX; OBLIMERSEN; PROTEIN BCL 2; PROTEIN MCL 1; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; GENE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOBLASTIC LYMPHOMA;

EID: 81555221746     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/524308     Document Type: Review

References (138)

1. Yuan J., Lipinski M., Degterev A., Diversity in the mechanisms of neuronal cell death Neuron 2003 40 2 401 413 (Pubitemid 37244104)
2. Zimmermann K. C., Green D. R., How cells die: apoptosis pathways Journal of Allergy and Clinical Immunology 2001 108 supplement 4 S99 S103 (Pubitemid 32978004)
3. Tait S. W. G., Green D. R., Mitochondria and cell death: outer membrane permeabilization and beyond Nature Reviews Molecular Cell Biology 2010 11 9 621 632
4. Green D. R., Reed J. C., Mitochondria and apoptosis Science 1998 281 5381 1309 1312 (Pubitemid 28406816)
5. Tsujimoto Y., Gorham J., Cossman J., The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining Science 1985 229 4720 1390 1393 (Pubitemid 16222379)
6. Cory S., Adams J. M., The BCL2 family: regulators of the cellular life-or-death switch Nature Reviews Cancer 2002 2 9 647 656 (Pubitemid 37328916)
7. Pickering B. M., De Mel S., Lee M., Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells Oncogene 2007 26 8 1166 1177
8. Walczak H., Krammer P. H., The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems Experimental Cell Research 2000 256 1 58 66 (Pubitemid 30211167)
9. Thomadaki H., Scorilas A., BCL2 family of apoptosis-related genes: functions and clinical implications in cancer Critical Reviews in Clinical Laboratory Sciences 2006 43 1 1 67 (Pubitemid 43379211)
10. Scorilas A., Kyriakopoulou L., Yousef G. M., Ashworth L. K., Kwamie A., Diamandis E. P., Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family Genomics 2001 72 2 217 221 (Pubitemid 32242963)
11. Talieri M., Diamandis E. P., Katsaros N., Gourgiotis D., Scorilas A., Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors Thrombosis and Haemostasis 2003 89 6 1081 1088 (Pubitemid 36798161)
12. Mathioudaki K., Scorilas A., Papadokostopoulou A., Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer Biological Chemistry 2004 385 9 779 783 (Pubitemid 39335299)
13. Thomadaki H., Talieri M., Scorilas A., Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer Cancer Letters 2007 247 1-2 48 55 (Pubitemid 44959407)
14. Thomadaki H., Talieri M., Scorilas A., Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS Biological Chemistry 2006 387 8 1081 1086 (Pubitemid 44200502)
15. Sklavounou A., Chrysomali E., Scorilas A., Karameris A., TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation Journal of Oral Pathology and Medicine 2000 29 8 370 375 (Pubitemid 30648009)
16. Kalomenidis I., Orphanidou D., Papamichalis G., Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics Lung 2001 179 5 265 278 (Pubitemid 34442213)
17. Reed J. C., Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities Cell Death and Differentiation 2006 13 8 1378 1386 (Pubitemid 44057473)
18. Adams J. M., Cory S., The Bcl-2 protein family: arbiters of cell survival Science 1998 281 5381 1322 1326 (Pubitemid 28406819)
19. Youle R. J., Strasser A., The BCL-2 protein family: opposing activities that mediate cell death Nature Reviews Molecular Cell Biology 2008 9 1 47 59
20. Reed J. C., Apoptosis mechanisms: implications for cancer drug discovery Oncology 2004 18 13 supplement 10 11 20
21. Korsmeyer S. J., Bcl-2: an antidote to programmed cell death Cancer Surveys 1992 15 105 118
22. Khemtemourian L., Sani M. A., Bathany K., Grobner G., Dufourc E. J., Synthesis and secondary structure in membranes of the Bcl-2 anti-apoptotic domain BH4 Journal of Peptide Science 2006 12 1 58 64 (Pubitemid 43033699)
23. Simonen M., Keller H., Heim J., The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis European Journal of Biochemistry 1997 249 1 85 91 (Pubitemid 27432599)
24. Bellows D. S., Chau B. N., Percy L., Lazebnik Y., Burns W. H., Hardwick J. M., Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins Journal of Virology 2000 74 11 5024 5031 (Pubitemid 30313841)
25. Yang-Yen H. F., Mcl-1: a highly regulated cell death and survival controller Journal of Biomedical Science 2006 13 2 201 204
26. Stewart D. P., Koss B., Bathina M., Perciavalle R. M., Bisanz K., Opferman J. T., Ubiquitin-independent degradation of antiapoptotic MCL-1 Molecular and Cellular Biology 2010 30 12 3099 3110
27. Akgul C., Mcl-1 is a potential therapeutic target in multiple types of cancer Cellular and Molecular Life Sciences 2009 66 8 1326 1336
28. Leibowitz B., Yu J., Mitochondrial signaling in cell death via the Bcl-2 family Cancer Biology and Therapy 2010 9 6 417 422
29. Petros A. M., Olejniczak E. T., Fesik S. W., Structural biology of the Bcl-2 family of proteins Biochimica et Biophysica Acta 2004 1644 2-3 83 94 (Pubitemid 38281265)
30. Walensky L. D., BCL-2 in the crosshairs: tipping the balance of life and death Cell Death and Differentiation 2006 13 8 1339 1350 (Pubitemid 44057469)
31. Klee M., Pimentel-Muinos F. X., Bcl-X(L) specifically activates Bak to induce swelling and restructuring of the endoplasmic reticulum Journal of Cell Biology 2005 168 5 723 734 (Pubitemid 40328157)
32. Chipuk J. E., Kuwana T., Bouchier-Hayes L., Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis Science 2004 303 5660 1010 1014 (Pubitemid 38209704)
33. Wood D. E., Thomas A., Devi L. A., Bax cleavage is mediated by calpain during drug-induced apoptosis Oncogene 1998 17 9 1069 1078 (Pubitemid 28444591)
34. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J., Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 1996 87 4 619 628 (Pubitemid 26386936)
35. Zhu Y., Yang G. Y., Ahlemeyer B., Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage Journal of Neuroscience 2002 22 10 3898 3909 (Pubitemid 37465698)
36. Zinkel S., Gross A., Yang E., BCL2 family in DNA damage and cell cycle control Cell Death and Differentiation 2006 13 8 1351 1359 (Pubitemid 44057470)
37. Zinkel S. S., Ong C. C., Ferguson D. O., Proapoptotic BID is required for myeloid homeostasis and tumor suppression Genes and Development 2003 17 2 229 239 (Pubitemid 36105895)
38. Wang K., Yin X. M., Chao D. T., Milliman C. L., Korsmeyer S. J., BID: a novel BH3 domain-only death agonist Genes and Development 1996 10 22 2859 2869 (Pubitemid 26394246)
39. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X., Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors Cell 1998 94 4 481 490 (Pubitemid 28391864)
40. Werner A. B., Tait S. W. G., De Vries E., Eldering E., Borst J., Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens Journal of Biological Chemistry 2004 279 27 28771 28780 (Pubitemid 38900162)
41. Kuwana T., Bouchier-Hayes L., Chipuk J. E., BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly Molecular Cell 2005 17 4 525 535 (Pubitemid 40269117)
42. Wojcik I., Szybka M., Golanska E., Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias Neoplasma 2005 52 4 318 324 (Pubitemid 41076200)
43. Menendez P., Vargas A., Bueno C., Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation Leukemia 2004 18 3 491 498 (Pubitemid 38425863)
44. Campana D., Coustan-Smith E., Manabe A., Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein Blood 1993 81 4 1025 1031 (Pubitemid 23054841)
45. Aref S., Salama O., Al-Tonbary Y., Mansour A., Assessment of bcl-2 expression ass modulator of Fas mediated apoptosis in acute leukemia Hematology 2004 9 2 113 121 (Pubitemid 38697025)
46. Sahu G. R., Das B. R., Prognostic significance of p53 and Bcl-2 in acute lymphoblastic leukemia Oncology Reports 2002 9 6 1391 1398
47. Campos L., Sabido O., Sebban C., Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia Leukemia 1996 10 3 434 438 (Pubitemid 26128781)
48. Hogarth L. A., Hall A. G., Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia Blood 1999 93 8 2671 2678 (Pubitemid 29181200)
49. Coustan-Smith E., Kitanaka A., Pui C. H., Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia Blood 1996 87 3 1140 1146 (Pubitemid 26043542)
50. Del Principe M. I., Del Poeta G., Maurillo L., P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia British Journal of Haematology 2003 121 5 730 738 (Pubitemid 36718189)
51. Feng H., Stachura D. L., White R. M., T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation Cancer Cell 2010 18 4 353 366
52. Prokop A., Wieder T., Sturm I., Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo Leukemia 2000 14 9 1606 1613
53. Swanson P. J., Kuslak S. L., Fang W., Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc Journal of Immunology 2004 172 11 6684 6691 (Pubitemid 38669104)
54. Addeo R., Caraglia M., Baldi A., Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL) Cancer Biology and Therapy 2005 4 1 32 38 (Pubitemid 41350927)
55. Mata J. F., Silveira V. S., Mateo E. C., Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL) Pediatric Blood and Cancer 2010 55 1 100 107
56. Laane E., Tani E., Bjorklund E., Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma Cytometry Part B 2005 64 1 34 42 (Pubitemid 40960410)
57. Ploner C., Rainer J., Lobenwein S., Geley S., Kofler R., Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells Apoptosis 2009 14 6 821 828
58. Holleman A., Den Boer M. L., De Menezes R. X., The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia Blood 2006 107 2 769 776 (Pubitemid 43076404)
59. Andreeff M., Jiang S., Zhang X., Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid Leukemia 1999 13 11 1881 1892 (Pubitemid 29535275)
60. Milojkovic D., Devereux S., Westwood N. B., Mufti G. J., Thomas N. S. B., Buggins A. G. S., Antiapoptotic microenvironment of acute myeloid leukemia Journal of Immunology 2004 173 11 6745 6752 (Pubitemid 39541060)
61. Buggins A. G. S., Milojkovic D., Arno M. J., Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways Journal of Immunology 2001 167 10 6021 6030 (Pubitemid 33062801)
62. Venditti A., Del Poeta G., Maurillo L., Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia Haematologica 2004 89 8 934 939 (Pubitemid 39049901)
63. Wuchter C., Karawajew L., Ruppert V., Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics Leukemia 1999 13 12 1943 1953
64. Kornblau S. M., Thall P. F., Estrov Z., The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics Clinical Cancer Research 1999 5 7 1758 1766 (Pubitemid 29334457)
65. Klampfer L., Zhang J., Zelenetz A. O., Uchida H., Nimer S. D., The AML1/ETO fusion protein activates transcription of BCL-2 Proceedings of the National Academy of Sciences of the United States of America 1996 93 24 14059 14064 (Pubitemid 26424245)
66. Shikami M., Miwa H., Nishii K., Low BCL-2 expression in acute leukemia with t(8;21) chromosomal abnormality Leukemia 1999 13 3 358 368 (Pubitemid 29108074)
67. Karakas T., Maurer U., Weidmann E., Miething C. C., Hoelzer D., Bergmann L., High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia Annals of Oncology 1998 9 2 159 165 (Pubitemid 28123617)
68. Kohler T., Schill C., Deininger M. W., High bad and bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML) Leukemia 2002 16 1 22 29 (Pubitemid 34105595)
69. Ong Y. L., McMullin M. F., Bailie K. E. M., Lappin T. R. J., Jones F. G. C., Irvine A. E., High bax expression is a good prognostic indicator in acute myeloid leukaemia British Journal of Haematology 2000 111 1 182 189
70. Yamaguchi H., Inokuchi K., Dan K., The study for loss of bcl-xs expression as a prognostic factor in acute myeloid leukemia Leukemia Research 2002 26 12 1119 1123 (Pubitemid 35346407)
71. Kornblau S. M., Vu H. T., Ruvolo P., BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia Clinical Cancer Research 2000 6 4 1401 1409 (Pubitemid 30226227)
72. Rochlitz C., Lohri A., Bacchi M., Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) Leukemia 1999 13 9 1352 1358 (Pubitemid 29429761)
73. Bradbury D., Rogers S., Kozlowski R., Bowen G., Reilly I. A. G., Russell N. H., Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia British Journal of Haematology 1990 76 4 488 493
74. Spiegel S., Milstien S., Sphingosine-1-phosphate: an enigmatic signalling lipid Nature Reviews Molecular Cell Biology 2003 4 5 397 407 (Pubitemid 36565571)
75. Turzanski J., Grundy M., Russell N. H., Pallis M., Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways Leukemia 2004 18 10 1662 1670 (Pubitemid 39386345)
76. Asao H., Fu X. Y., Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation Journal of Biological Chemistry 2000 275 2 867 874 (Pubitemid 30051128)
77. Faderl S., Harris D., Van Q., Kantarjian H. M., Talpaz M., Estrov Z., Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia Blood 2003 102 2 630 637 (Pubitemid 36841985)
78. Milella M., Estrov Z., Kornblau S. M., Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia Blood 2002 99 9 3461 3464 (Pubitemid 34525332)
79. Karnolsky I. N., Cytogenetic abnormalities in chronic lymphocytic leukemia Folia Medica 2000 42 3 5 10
80. Cimmino A., Calin G. A., Fabbri M., miR-15 and miR-16 induce apoptosis by targeting BCL2 Proceedings of the National Academy of Sciences of the United States of America 2005 102 39 13944 13949 (Pubitemid 41377683)
81. Calin G. A., Cimmino A., Fabbri M., MiR-15a and miR-16-1 cluster functions in human leukemia Proceedings of the National Academy of Sciences of the United States of America 2008 105 13 5166 5171 (Pubitemid 351738528)
82. Nuckel H., Frey U. H., Bau M., Association of a novel regulatory polymorphism (-938 C A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia Blood 2007 109 1 290 297 (Pubitemid 46053069)
83. Majid A., Tsoulakis O., Walewska R., BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938 C A promoter single nucleotide polymorphism Blood 2008 111 2 874 877
84. Pepper C., Hoy T., Bentley P., Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance Leukemia and Lymphoma 1998 28 3-4 355 361 (Pubitemid 28105041)
85. Skogsberg S., Tobin G., Krober A., The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia Leukemia 2006 20 1 77 81
86. Moshynska O., Sankaran K., Pahwa P., Saxena A., Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia Journal of the National Cancer Institute 2004 96 9 673 682 (Pubitemid 38660230)
87. Packham G., Stevenson F. K., Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia Immunology 2005 114 4 441 449 (Pubitemid 40478137)
88. Kitada S., Andersen J., Akar S., Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses Blood 1998 91 9 3379 3389 (Pubitemid 28193890)
89. Robertson L. E., Plunkett W., McConnell K., Keating M. J., McDonnell T. J., Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome Leukemia 1996 10 3 456 459 (Pubitemid 26128784)
90. Molica S., Dattilo A., Giulino C., Levato D., Levato L., Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease Haematologica 1998 83 12 1122 1124 (Pubitemid 29065932)
91. Aguilar-Santelises M., Rottenberg M. E., Lewin N., Mellstedt H., Jondal M., bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression International Journal of Cancer 1996 69 2 114 119 (Pubitemid 26167166)
92. Molica S., Mannella A., Crispino G., Dattilo A., Levato D., Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias Haematologica 1997 82 5 555 559 (Pubitemid 28023248)
93. Faderl S., Keating M. J., Do K. A., Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL) Leukemia 2002 16 6 1045 1052 (Pubitemid 34618843)
94. Faria J. R., Yamamoto M., Faria R. M. D., Kerbauy J., Oliveira J. S. R., Fludarabine induces apoptosis in chronic lymphocytic leukemiathe role of P53, Bcl-2, Bax, Mcl-1 and Bag-1 proteins Brazilian Journal of Medical and Biological Research 2006 39 3 327 333 (Pubitemid 43349467)
95. Morales A. A., Olsson A., Celsing F., Osterborg A., Jondal M., Osorio L. M., High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia International Journal of Cancer 2005 113 5 730 737 (Pubitemid 40101253)
96. Olsson A., Norberg M., Okvist A., Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia British Journal of Cancer 2007 97 6 769 777 (Pubitemid 47396296)
97. Saxena A., Viswanathan S., Moshynska O., Tandon P., Sankaran K., Sheridan D. P., Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia American Journal of Hematology 2004 75 1 22 33 (Pubitemid 38040164)
98. Klobusicka M., Kusenda J., Babusikova O., Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients Neoplasma 2002 49 6 387 393 (Pubitemid 36139239)
99. Lazaridou A., Miraxtsi C., Korantzis J., Eleftheriadis N., Christakis J. I., Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and p53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status Leukemia and Lymphoma 2000 36 5-6 503 512 (Pubitemid 30103175)
100. Duensing S., Nasarek A., Grosse J., Ganser A., Atzpodien J., Elevated plasma levels of interleukin-1 receptor antagonist are associated with decreased cellular BCL-2 oncoprotein expression in B-chronic lymphocytic leukemia Cancer Biotherapy and Radiopharmaceuticals 1998 13 5 383 385 (Pubitemid 29011311)
101. Furman R. R., Asgary Z., Mascarenhas J. O., Liou H. C., Schattner E. J., Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells Journal of Immunology 2000 164 4 2200 2206 (Pubitemid 30108780)
102. Cuni S., Perez-Aciego P., Perez-Chacon G., A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells Leukemia 2004 18 8 1391 1400 (Pubitemid 39136749)
103. Zhuang J., Hawkins S. F., Glenn M. A., Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition Haematologica 2010 95 1 110 118
104. Jaiswal S., Traver D., Miyamoto T., Akashi K., Lagasse E., Weissman I. L., Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias Proceedings of the National Academy of Sciences of the United States of America 2003 100 17 10002 10007 (Pubitemid 37087058)
105. Handa H., Hegde U. P., Kotelnikov V. M., Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase Leukemia Research 1997 21 6 479 489 (Pubitemid 27384902)
106. Freytag S. O., Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1 Molecular and Cellular Biology 1988 8 4 1614 1624
107. Shuai K., Halpern J., Hoeve J. T., Rao X., Sawyers C. L., Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia Oncogene 1996 13 2 247 254 (Pubitemid 26334856)
108. Darnell J. E. Jr., STATs and gene regulation Science 1997 277 5332 1630 1635 (Pubitemid 27446219)
109. Neshat M. S., Raitano A. B., Wang H. G., Reed J. C., Sawyers C. L., The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf Molecular and Cellular Biology 2000 20 4 1179 1186 (Pubitemid 30069238)
110. Keeshan K., Cotter T. G., McKenna S. L., High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion Leukemia 2002 16 9 1725 1734
111. Shinjyo T., Kuribara R., Inukai T., Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors Molecular and Cellular Biology 2001 21 3 854 864 (Pubitemid 32104733)
112. Kuribara R., Honda H., Matsui H., Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors Molecular and Cellular Biology 2004 24 14 6172 6183 (Pubitemid 38891120)
113. Aichberger K. J., Mayerhofer M., Krauth M. T., Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides Blood 2005 105 8 3303 3311
114. O'Brien S. M., Cunningham C. C., Golenkov A. K., Turkina A. G., Novick S. C., Rai K. R., Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia Journal of Clinical Oncology 2005 23 30 7697 7702 (Pubitemid 46291834)
115. van de Donk N. W. C., Kamphuis M. M. J., van Dijk M., Borst H. P. E., Bloem A. C., Lokhorst H. M., Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein Leukemia 2003 17 1 211 219 (Pubitemid 36175908)
116. Smith M. R., Abubakr Y., Mohammad R., Xie T., Hamdan M., al-Katib A., Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL Cancer Gene Therapy 1995 2 3 207 212
117. Keating M. J., O'Brien S., Albitar M., Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia Journal of Clinical Oncology 2005 23 18 4079 4088 (Pubitemid 46211313)
118. Chanan-Khan A., Bcl-2 antisense therapy in B-cell malignancies Blood Reviews 2005 19 4 213 221 (Pubitemid 40387412)
119. Marcucci G., Stock W., Dai G., Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity Journal of Clinical Oncology 2005 23 15 3404 3411
120. Marcucci G., Byrd J. C., Dai G., Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia Blood 2003 101 2 425 432 (Pubitemid 36077559)
121. Giles F. J., New drugs in acute myeloid leukemia Current Oncology Reports 2002 4 5 369 374
122. Floros K. V., Talieri M., Scorilas A., Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells Biological Chemistry 2006 387 12 1629 1633 (Pubitemid 44837589)
123. Floros K. V., Thomadaki H., Florou D., Talieri M., Scorilas A., Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide Annals of the New York Academy of Sciences 2006 1090 89 97 (Pubitemid 47092111)
124. Floros K. V., Thomadaki H., Katsaros N., Taileri M., Scorilas A., mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin Biological Chemistry 2004 385 11 1099 1103 (Pubitemid 39600320)
125. Floros K. V., Thomadaki H., Lallas G., Katsaros N., Talieri M., Scorilas A., Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12 Annals of the New York Academy of Sciences 2003 1010 153 158 (Pubitemid 38264966)
126. Thomadaki H., Karaliota A., Litos C., Scorilas A., Enhanced antileukemic activity of the novel complex 2,5-dihydroxybenzoate molybdenum(VI) against 2,5-dihydroxybenzoate, polyoxometalate of Mo(VI), and tetraphenylphosphonium in the human HL-60 and K562 leukemic cell lines Journal of Medicinal Chemistry 2007 50 6 1316 1321 (Pubitemid 46496330)
127. Thomadaki H., Karaliota A., Litos C., Scorilas A., Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine) 2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines Journal of Medicinal Chemistry 2008 51 13 3713 3719 (Pubitemid 351956503)
128. Thomadaki H., Floros K. V., Scorilas A., Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12 Annals of the New York Academy of Sciences 2009 1171 276 283
129. Tse C., Shoemaker A. R., Adickes J., ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Research 2008 68 9 3421 3428
130. Kang M. H., Kang H. K., Szymanska B., Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo Blood 2007 110 6 2057 2066 (Pubitemid 47443923)
131. Kang M. H., Wan Z., Kang Y. H., Sposto R., Reynolds C. P., Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation Journal of the National Cancer Institute 2008 100 8 580 595
132. Del Gaizo Moore V., Schlis K. D., Sallan S. E., Armstrong S. A., Letai A., BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia Blood 2008 111 4 2300 2309 (Pubitemid 351451437)
133. Oltersdorf T., Elmore S. W., Shoemaker A. R., An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 7042 677 681 (Pubitemid 40825512)
134. Vogler M., Butterworth M., Majid A., Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia Blood 2009 113 18 4403 4413
135. Vogler M., Dinsdale D., Sun X. M., A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells Cell Death and Differentiation 2008 15 5 820 830 (Pubitemid 351524424)
136. Vogler M., Furdas S. D., Jung M., Kuwana T., Dyer M. J. S., Cohen G. M., Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood Clinical Cancer Research 2010 16 16 4217 4225
137. Del Gaizo Moore V., Brown J. R., Certo M., Love T. M., Novina C. D., Letai A., Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 Journal of Clinical Investigation 2007 117 1 112 121 (Pubitemid 46048458)
138. Mason K. D., Khaw S. L., Rayeroux K. C., The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia Leukemia 2009 23 11 2034 2041